VCP979, a novel p38MAPK inhibitor, attenuates inflammatory response and improve cardiac function post-myocardial infarction

29 August 2017 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 6 - Chronic heart failure (CHF) Pharmacologic therapy ESC Premium Access ESC Congress 2017